Skip to main content

Oregon State Flag An official website of the State of Oregon »

Oregon Health Authority logo

Evidence-based Reports Blog

BlogTopic

Ablation for Atrial Fibrillation



 
  
  
  
There are no items to show in this view of the "Evidence-based Reports" document library.

 

BlogEntry

10/6/2016

The Commission placed this coverage guidance on "passive monitoring." Interested stakeholders can request a review by contacting herc.info@odhs​​oha.oregon.gov​.

1/8/2015

HERC reviewed and approved the draft coverage guidance and related Prioritized List changes as presented in the meeting materials.

11/13/2014

VbBS reviewed the draft coverage guidance and recommended prioritization changes. See meeting materials for recomm​endations.

9/4/2014

The EbGS reviewed public comments and heard public testimony on the draft coverage guidance, made revisions, and referred it to the VbBS and HERC for prioritization changes and approval. The VbBS will review the draft coverage guidance at its meeting on 11/13/2014.

6/20/14 to 8 a.m. 7/22/2014

​The draft coverage guidance has been posted for a 30-day comment period. Rules for offering public comment are posted on our Coverage Guidance Open for Co​mment ​page.​​

5/5/2014

EbGS will discuss this topic at its June 5, 2014 meeting. Sources are:

Al-Khatib, S.M., Allen Lapointe, N., Chatterjee, R., Crowley, M.J., Dupre, M.E., Kong, D.F., et al. (2013). Treatment of atrial fibrillation. Comparative Effectiveness Review 119. (Prepared by the Duke Evidence-based Practice Center under Contract No. 290-2007-10066-I.) AHRQ Publication No.13-EHC095-EF. Rockville, MD: Agency for Healthcare Research and Quality. Retrieved from www.effectivehealthcare.ahrq.gov/re​ports/final.cfm

Chen, H.S., Wen, J.M., Wu, S.N., & Liu, J.P. (2012). Catheter ablation for paroxysmal and persistent atrial fibrillation. Cochrane Database of Systematic Reviews, Issue 4. Art. No.: CD007101. DOI: 10.1002/14651858.CD007101.pub2. Retrieved from http://summaries.cochrane.org/CD007101/catheter-ablation-would-be-an-alternative-to-inhibit-recurrence-of-paroxysmal-or-persistent-atrial-fibrillation (link no longer valid)

Hashimoto, R.E., Raich, A., Junge, M., & Skelly, A. (2013). Catheter ablation procedures for supraventricular tachyarrhythmia, including atrial flutter & atrial fibrillation. Olympia, WA: Washington State Health Care Authority Health Technology Assessment Program. Retrieved from http://www.hca.wa.gov/hta/Pages/Forms/HTA_Findings.aspx (link no longer valid)

January, C.T., Wann, L.S., Alpert, J.S., Calkins, H., Cleveland, Jr, J.C., Cigarroa, J.E., et al. (2014). 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation, 129. doi:10.1161/CIR.0000000000000041. Retrieved from http://circ.ahajournals.org/content/early/2014/03/27/CIR.0000000000000041.citation (link no longer valid)

5/16/2019

VbBS will address this topic at its August 8, 2019 meeting; no coverage guidaance is forthcoming.

3/9/2017

​The draft scope statement was discussed at the 2/16/2017 HTAS meeting. The topic was considered for selection at the March 9, 2017 HERC meeting.

2/16/2017

​HTAS will review the draft scope statement recommendations at its meeting and may refer them to HERC for consideration in topic selection.

1/27/2017-2/6/2017

​Scope statement posted for public comment date range 1/27/2017-2/6/2017, 8:00 am 

This topic is under consideration for creation of a new coverage guidance. HERC will decide on next topics for coverage guidance development at its March 9, 2017 HERC meeting.

 

3/9/2017

​The Health Evidence Review Commission reaffirmed the previously approved coverage guidance. It is now on "passive monitoring." Stakeholders can contact staff at herc.info@​state.or.us for consideration of updating this coverage guidance.

9/1/2016

​EbGS reviewed the draft scope statement.

8/9/2012

The HERC reviewed the draft coverage guidance as referred by the EbGS on August 2, 2012 and approved it.

5/3/2012

The EbGS reviewed the initial draft coverage guidance on May 3, 2012.

10/6/2016

The Commission placed this coverage guidance on "passive monitoring." Interested stakeholders can request a review by contacting herc.info@dhsoh​a.state.or.us.

1/8/2015

​VbBS reviewed and made Prioritized List change recommendations, which included changes from the meeting materials. HERC approved the draft coverage guidance and related Prioritized List changes as modified during the meeting.

11/24/2014

HTAS reviewed the draft coverage guidance. HERC and VbBS will review the draft coverage guidance and potential associated potential prioritization changes at their meetings 1/8/2015.

9/25/2014 to 8 a.m. 10/27/2014

The draft coverage guidance has been posted for a 30-day comment period. Rules for offering public comment are posted on our Coverage Guidance O​pen for Comment page.

8/22/2014

The title for the coverage guidance previously called PET/CT/Radionuclide in Staging for Prostate Cancer has been changed. The new title is Advanced Imaging in Staging of Prostate Cancer.

8/13/2014

​The source report has been posted for this topic:

Trusted source:
National Institute for Health and Clinical Excellence, (2014). Prostate Cancer: diagnosis and treatment. London: National Institute for Health and Clinical Excellence. Retrieved 6/25/14 from http://guidance.nice.org.uk/CG17​5/Guidance

5/17/2018

The coverage guidance Prostatic Urethral Lifts ​for Benign Prostatic Hypertrophy was approved. It supersedes a portion of this coverage guidance and recommends coverage for prostatic urethral lifts.​

3/26/2018

​A new coverage guidance on ​Prostatic Urethral Lif​ts for Benign Prostatic Hypertrophy is under development. When approved, it will supersede the portions of this coverage guidance related to Prostatic Urethral Lifts.

10/6/2016

The Commission placed this coverage guidance on "passive monitoring." Interested stakeholders can request a review by contacting herc.info​@dhsoha.state.or.us.

3/12/2015

HERC reviewed and approved the draft coverage guidance and related Prioritized List changes as presented in the meeting materials.

2/26/2015

HERC will review the draft coverage guidance on 3/12/2015.

2/23/2015

HTAS reviewed public comment and referred the draft coverage guidance to the VbBS and HERC.

1/23/2015

​New sources:
 
Ahyai, S. A., Gilling, P., Kaplan, S. A., Kuntz, R. M., Madersbacher, S., Montorsi, F, et al. (2010). Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. European urology,58(3), 384-397. doi:10.1016/j.eururo.2010.06.005. Retrieved from http://www.ncbi.nlm.nih.gov/pub​​medhealth/PMH0029840/
 
Bachmann, A.,Tubaro, A., Barber, N., d’Ancona, F., Muir, G., Witzsch, U., et al. (2014). 180-W XPS GreenLight Laser Vaporization Versus Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: 6-Month Safety and Efficacy Results of a European Multicentre Randomised Trial – The GOLIATH Study. European urology, 65, 931-42. doi: 10.1016/j.eururo.2013.10.040.
 
Cornu, J. N., Ahyai, S., Bachmann, A., de la Rosette, J., Gilling, P., Gratzke, C., et al. (2014). A systematic review and meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic obstruction: an update. European urology. doi: 10.1016/j.eururo.2014.06.017.
 
Lee, S. W., Choi, J. B., Lee, K. S., Kim, T. H., Son, H., Jung, T. Y., ... & Kim, J. C. (2013). Transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement: a quality and meta-analysis.International neurourology journal17(2), 59-66. doi: 10.5213/inj.2013.17.2.59.Retrieved from http://synapse.koreamed.org/Synapse/Data/PDFData/1092INJ/inj-17-59.pdf  (link no longer valid)
 

11/24/2014

​HTAS reviewed the draft coverage guidance, made revisions and posted it for public co​mment, 12/4/2014 to 8:00 a.m. 12/26/2014.

11/20/2014

Updated draft covera​ge guidance​ posted as handout for the 11/24/2014 HTAS meeting.

9/26/2014 to 8 a.m. 10/28/2014

The draft coverage guidance has been posted for a 30-day comment period. Rules for offering public comment are posted on our Coverage Guidance Open fo​r Comment page.

8/13/2014

Sources have been posted for this topic:
 
Trusted sources:
National Institute for Health and Clinical Excellence, (2010). Management of lower urinary tract symptoms in men. London: National Institute for Health and Clinical Excellence. Retrieved from http://www.nice.org.uk/guidance/cg97​
 
National Institute for Health and Clinical Excellence, (2013). Interventional procedure guidance 453: Prostate artery embolisation for benign prostatic hyperplasia. London: National Institute for Health and Clinical Excellence. Retrieved from www.nice.org.uk/guida​nce/ipg453

National Institute for Health and Clinical Excellence, (2014). Interventional procedure guidance 475: Insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia. Retrieved from www.nice.org.uk/guidance/ipg475 (3/23/16 note: Link removed; no longer valid)
 
Hatem, M., Sandall, J., Devane, D., Soltani, H., & Gates, S. (2008). Midwife-led versus other models of care for childbearing women. Cochrane Database of Systematic Reviews, 4(10).

7/28/2014

Topic name changed from "Surgical Treatment of Lower Urinary Tract Symptoms in Men" to "Alternatives to Transurethral Resection of the Prostate."

6/24/2014

The HTAS will discuss the initial draft coverage guidance at its meet​ing on 9/22/2014 at 1 p.m.
 
Initial sources for the report are:
 
National Institute for Health and Clinical Excellence, (2013). Interventional procedure guidance 453: Prostate artery embolisation for benign prostatic hyperplasia. London: National Institute for Health and Clinical Excellence. Retrieved from www.nice.org.uk/nicemedia/live/13705/63679/63679.pdf  (link not active 9/11/2015)

National Institute for Health and Clinical Excellence, (2014). Interventional procedure guidance 475: Insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia. Retrieved from www.nice.org.uk/nicemedia/live/13967/66323/66323.pdf (link not active 8/17/2015)

National Institute for Health and Clinical Excellence, (2010). Management of lower urinary tract symptoms in men. London: National Institute for Health and Clinical Excellence. Retrieved from http://www.nice.org.uk/guidance/cg97​ (link no longer valid)

9/4/2014

​EbGS made conforming changes to the evidence evaluation as requested by HERC on 8/14/2014. Changes to coverage under the Oregon Health Plan will be effective January 1, 2015.

8/14/2014

​The Health Evidence Review Commission reviewed and approved the evidence evaluation and associated prioritization and guideline note changes, but also referred the evidence evaluation back to EbGS for alignment with parity rules. Reviewed Evidence Evaluation and Prioritized List Changes

6/12/2014

​The Value-based benefits Subcommittee reviewed the draft evidence evaluation and approved guideline note changes for the Prioritized List.

5/8/2014

​The Value-based Benefits subcommittee discussed the draft evaluation of evidence at its meeting and deferred a decision until its next meeting, which will occur June 12, 2014.

5/6/2014

​Posted current d​raft evaluation of evidence, including changes from 4/24/2014 EbGS meeting.

4/24/2014

​The EbGS made revisions to the draft evaluation of evidence and referred it to the Health Evidence Review Commission. A revised draft will be posted as soon as possible.

3/20/2014

​The EbGS began its review of public comment but did not approve the draft evidence evaluation. The subcommittee will continue its review of public comments and complete its evaluation of the evidence on 4/24/2014.

2/18/2014

​Citation:
Therapies for children with autism spectrum disorder – Behavioral interventions update. Draft Comparative Effectiveness Review. Rockville, MD: Agency for Healthcare Research and Quality. Retrieved January 27, 2014, from http://effectivehealthcare.ahrq.gov/search-for-guides-reviews-and-repo​rts/?pageaction=displayProduct&productID=1845

2/12/2014

​As a result of the cancellation of the 2/6/14 EbGS meeting, a new replacement meeting has been scheduled for 3/20/2014 at 2 p.m. In addition, the EbGS meeting previously scheduled for 4/3/2014 has been rescheduled to 4/24/2014. Locations for both meetings are yet to be determined.

2/6/2014

​EbGS meeting cancelled due to inclement weather and unforeseen circumstances.

12/16/2013

​Public comment period ended at 8:00 am.

11/14/13 - OPEN FOR PUBLIC COMMENT 11/14/13-12/16/13 (at 8 a.m.)

​The Draft Evaluation of Evidence has been posted for a 30-day comment period. Rules for offering public comment will follow those listed on our Coverage Guidance Open for Comment page.

11/7/2013

​The EbGS continued the discussion of the draft Evaluation of Evidence and heard testimony from appointed experts and members of the public. The subcommittee voted to revise the draft and post it for a 30-day public comment period. The revised draft will posted by next week, and the subcommittee plans to review written public comments at the EbGS meeting 2/6/2014.

10/4/2013

​HERC recently received permission to post these refer​ences to evidence sources used in developing the Evaluation of Evidence. They will be added as an appendix to the next version of the Evaluation of Evidence when it is posted.

9/12/2013

​The EbGS reviewed the draft Evaluation of Evidence, heard public testimony and will continue discussion at its 11/7/13 meeting.
Applied Behavior Analysis for Autism Spectrum Disorders Brief.pdf
Applied Behavior Analysis for Autism Spectrum Disorders DRAFT for EbGS Meeting Materials 9-12-2013.pdf
Sources

Invited comments for the 9/12/13 EbGS meeting: Presentations​ from: Green, Reichow, Hagopian, Legaard

8/8/2013

​HERC directed EbGS to review the evidence. 

3/9/2017

​The Health Evidence Review Commission reaffirmed the previously approved coverage guidance. It is now on "passive monitoring." Stakeholders can contact staff at herc.info@st​ate.or.us for consideration of updating this coverage guidance.

1 - 50Next